Follow CGSP on Social Media

Listen to the CGSP Podcast

How Does Sinovac’s Efficacy Rate Compare to Other COVID-19 Vaccines?

For the past two weeks, we’ve been discussing the efficacy rates of Chinese vaccines compared to those from other countries and a number of readers have asked for comparative data to measure how jabs from the likes of Sinovac perform against AstraZeneca’s in particular.

Sinovac’s jab that uses inactive agents performs poorly against the more advanced mRNA vaccines from Pfizer, Moderna, and even Russia’s Sputnik V in phase three clinical trials. However, that 50% efficacy rate for Sinovac is only for mild cases. In terms of severe illness or death, it performs at almost 100% which is critical for developing countries because it lowers hospital admission rates.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Global South Project?


The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.